Page 6 - Comparative Effectiveness News Today

New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years the longest follow-up of any Bruton's tyrosine kinase inhibitor in multiple

Childhood trauma does not hinder progress in patients treated for bipolar disorder (BD) according to a recent published study.

Low-dose dutasteride, other oral agents top the ranking in efficacy in a meta-analysis; however, side effects need consideration, experts note.

One of the more depressing things about getting much more interested in the debate over how we should screen for common cancers, particularly breast and prostate cancer, is my increasing realization of just how little physicians themselves understand about the complexities involved in weighing the value of such tests. It's become increasingly apparent to me that most physicians believe that early detection is always good and that it always saves lives, having little or no conception of lead...

In the United States, maternal mortality rates remain higher than in comparable countries, and racial disparities persist. While many countries have

Panel suggests that laser resurfacing does not have to be delayed at least 6 months post isotretinoin in acne patients.

A new study provided evidence of a lower 24-week risk of COVID-19–related outcomes among recipients of the mRNA-1273 vaccine, compared to their counterparts who received the BNT162b2 vaccine.

Although some panel members backed the drug for emergency use, there were still a lot of concerns because of a lack of safety and efficacy data.

BATON ROUGE, La. – Skymount Medical has partnered with Riverside University Health System, or RUHS, Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral

According to a Friday morning news release from Louisiana State University (LSU), Skymount Medical has partnered with Riverside University Health System, or RUHS, Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by LSU researchers using artificial intelligence, or AI.